A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT ID: NCT05620823
Last Updated: 2026-02-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
608 participants
INTERVENTIONAL
2022-12-19
2025-12-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
NCT05620836
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06212999
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000
Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06118099
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
NCT06516952
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Povorcitinib Dose A
Participants will receive Povorcitinib Dose A for 54 weeks.
Povorcitinib
Oral; Tablet
Povorcitinib Dose B
Participants will receive Povorcitinib Dose B for 54 weeks.
Povorcitinib
Oral; Tablet
Placebo
Participants will receive Placebo for 12 weeks, followed by Povorcitinib (Dose A or Dose B) for 42 weeks.
Placebo
Oral; Tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Povorcitinib
Oral; Tablet
Placebo
Oral; Tablet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Total abscess and inflammatory nodule count of at least 5 at both the screening and baseline visits
* HS lesions in at least 2 distinct anatomical areas (examples include but are not limited to left and right axilla or left and right inguinocrural fold), 1 of which must be at least Hurley Stage II or Hurley Stage III, at both the screening and baseline visits
* Documented history of inadequate response to at least a 3-month course of at least 1 conventional systemic therapy (oral antibiotic or biologic drug) for HS (or demonstrated intolerance to, or have a contraindication to, a conventional systemic therapy for treatment of their HS).
* Agreement to NOT use topical and systemic antibiotics for treatment of HS during the placebo-controlled period.
* Agreement to NOT use a diluted bleach bath or topical antiseptic washes containing chlorhexidine gluconate or benzoyl peroxide on the areas affected by HS lesions during the placebo-controlled period. Note: Over-the-counter soap and water is allowed.
* Agreement to use contraception
* Willing and able to comply with the study protocol and procedures.
Exclusion Criteria
* Women who are pregnant (or who are considering pregnancy) or breastfeeding.
* Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.
* Laboratory values outside of the protocol-defined ranges.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Incyte Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Investigative Site US303
Phoenix, Arizona, United States
Investigative Site US335
Arkansas City, Arkansas, United States
Investigative Site US307
Fort Smith, Arkansas, United States
Investigative Site US315
Laguna Niguel, California, United States
Investigative Site US326
Los Angeles, California, United States
Investigative Site US323
San Francisco, California, United States
Investigative Site US306
Boca Raton, Florida, United States
Investigative Site US320
Boca Raton, Florida, United States
Investigative Site US317
Hialeah, Florida, United States
Investigative Site US338
Margate, Florida, United States
Investigative Site US321
North Miami Beach, Florida, United States
Investigative Site US316
Orlando, Florida, United States
Investigative Site US328
Tampa, Florida, United States
Investigative Site US336
Tampa, Florida, United States
Investigative Site US311
Marietta, Georgia, United States
Investigative Site US327
Chicago, Illinois, United States
Investigative Site US319
Skokie, Illinois, United States
Investigative Site US337
Indianapolis, Indiana, United States
Investigative Site US341
Bowling Green, Kentucky, United States
Investigative Site US334
Metairie, Louisiana, United States
Investigative Site US333
Baltimore, Maryland, United States
Investigative Site US325
Columbia, Maryland, United States
Investigative Site US318
Beverly, Massachusetts, United States
Investigative Site US304
Boston, Massachusetts, United States
Investigative Site US310
Brighton, Massachusetts, United States
Investigative Site US302
St Louis, Missouri, United States
Investigative Site US331
Albuquerque, New Mexico, United States
Investigative Site US324
Kew Gardens, New York, United States
Investigative Site US339
Bexley, Ohio, United States
Investigative Site US330
Boardman, Ohio, United States
Investigative Site US314
Cincinnati, Ohio, United States
Investigative Site US312
Cleveland, Ohio, United States
Investigative Site US301
Portland, Oregon, United States
Investigative Site US340
Bellaire, Texas, United States
Investigative Site US300
Plano, Texas, United States
Investigative Site US313
Norfolk, Virginia, United States
Investigative Site US308
Spokane, Washington, United States
Investigative Site AT304
Graz, , Austria
Investigative Site 00A
Innsbruck, , Austria
Investigative Site AT306
Innsbruck, , Austria
Investigative Site AT302
Linz, , Austria
Investigative Site AT305
Vienna, , Austria
Investigative Site AT301
Vienna, , Austria
Investigative Site AT300
Vienna, , Austria
Investigative Site BE300
Brussels, , Belgium
Investigative Site BE304
Brussels, , Belgium
Investigative Site BE301
Ghent, , Belgium
Investigative Site BE306
Ghent, , Belgium
Investigative Site BE305
Leuven, , Belgium
Investigative Site BE302
Liège, , Belgium
Investigative Site BE303
Namur, , Belgium
Investigative Site CA301
Winnipeg, Manitoba, Canada
Investigative Site CA304
Barrie, Ontario, Canada
Investigative Site CA308
Hamilton, Ontario, Canada
Investigative Site CA303
London, Ontario, Canada
Investigative Site CA302
Peterborough, Ontario, Canada
Investigative Site CA306
Laval, Quebec, Canada
Investigative Site CA307
Montreal, Quebec, Canada
Investigative Site CA309
Québec, Quebec, Canada
Investigative Site CZ301
Ostrava - Poruba, , Czechia
Investigative Site CZ300
Prague, , Czechia
Investigative Site FR305
Bordeaux, , France
Investigative Site FR303
Brest, , France
Investigative Site FR307
Le Mans, , France
Investigative Site FR304
Marseille, , France
Investigative Site FR302
Nantes, , France
Investigative Site FR300
Paris, , France
Investigative Site FR301
Saint-Priest-en-Jarez, , France
Investigative Site FR306
Toulouse, , France
Investigative Site DE305
Darmstadt, , Germany
Investigative Site DE302
Dresden, , Germany
Investigative Site DE306
Düsseldorf, , Germany
Investigative Site DE301
Frankfurt am Main, , Germany
Investigative Site DE303
Hamburg, , Germany
Investigative Site DE300
Hanover, , Germany
Investigative Site DE304
Langenau, , Germany
Investigative Site DE307
Memmingen, , Germany
Investigative Site GR300
Athens, , Greece
Investigative Site GR303
Athens, , Greece
Investigative Site GR301
Thessaloniki, , Greece
Investigative Site GR302
Thessaloniki, , Greece
Investigative Site JP304
Itabashi-ku, , Japan
Investigative Site JP305
Kurume-shi, , Japan
Investigative Site JP300
Kyoto, , Japan
Investigative Site JP301
Nakagami-gun, , Japan
Investigative Site JP303
Niigata, , Japan
Investigative Site JP307
Nishinomiya-shi, , Japan
Investigative Site JP308
Sapporo, , Japan
Investigative Site JP302
Sendai, , Japan
Investigative Site JP309
Shinjuku-ku, , Japan
Investigative Site JP306
Tsukuba, , Japan
Investigative Site NL302
Breda, , Netherlands
Investigative Site NL303
Groningen, , Netherlands
Investigative Site NL301
Rotterdam, , Netherlands
Investigative Site PL304
Ostrowiec, , Poland
Investigative Site PL303
Poznan, , Poland
Investigative Site PL301
Wroclaw, , Poland
Investigative Site PL302
Wroclaw, , Poland
Investigative Site ES302
Badalona, , Spain
Investigative Site ES303
Barcelona, , Spain
Investigative Site ES301
Granada, , Spain
Investigative Site ES305
Madrid, , Spain
Investigative Site ES300
Pontevedra, , Spain
Investigative Site ES304
Santiago de Compostela, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-501752-29-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
INCB 54707-301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.